By Professor David Thomas

Other

Nagrial A; Carlino MS; Gunjur A; Brown MP; Harris S; Underhill C; Zielinski R; Kee D; Lam W-S; Chan H; Harrup R; So J; Collins IM; Michael M; Chionh F; Uy C; Mariadason J; Torres J; Ballinger ML; Grady JP; Tavancheh E; Palmer J; Thomas DM; Wilkie K; Cebon J; Klein O, 2026, Data from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial, http://dx.doi.org/10.1158/1078-0432.c.8630732

Nagrial A; Carlino MS; Gunjur A; Brown MP; Harris S; Underhill C; Zielinski R; Kee D; Lam W-S; Chan H; Harrup R; So J; Collins IM; Michael M; Chionh F; Uy C; Mariadason J; Torres J; Ballinger ML; Grady JP; Tavancheh E; Palmer J; Thomas DM; Wilkie K; Cebon J; Klein O, 2026, Supplementary Table S1 from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial, http://dx.doi.org/10.1158/1078-0432.33143048

Cote GM; Aberoumand M; Choy E; Sebastian L; Mazzola E; Grimison P; Merriam P; Ballinger M; Thavaneswaran S; Lin F; Grady JP; Millward M; Brown MP; Harrup R; Espinoza D; Demetri G; Littlefield BA; Simes RJ; George S; Thomas D, 2026, Data from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma, http://dx.doi.org/10.1158/1078-0432.c.8509442

Cote GM; Aberoumand M; Choy E; Sebastian L; Mazzola E; Grimison P; Merriam P; Ballinger M; Thavaneswaran S; Lin F; Grady JP; Millward M; Brown MP; Harrup R; Espinoza D; Demetri G; Littlefield BA; Simes RJ; George S; Thomas D, 2026, Supplementary Tables 1-3 from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma, http://dx.doi.org/10.1158/1078-0432.32530688

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Data from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.c.8353092

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Figure 1 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744587

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Figure 2 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744584

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Supplementary Figure S1 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744581

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Supplementary Figure S2 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744578

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Supplementary Methods S1 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744575

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Supplementary Table S1 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744572

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Supplementary Table S2 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744569

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Supplementary Table S3 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744566

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Supplementary Table S4 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744563

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Supplementary Table S5 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744560

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Supplementary Table S6 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744557

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Table 1 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744554

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Table 2 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744548

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Table 3 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744545

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Table 4 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744539

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, Table 5 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors, http://dx.doi.org/10.1158/1078-0432.31744536

Back to profile page